JPRN-UMIN000013502已完成未知
Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations. - Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Symptomatic brain metastasis. 2)Patients with untreated brain metastases of size 3cm or more. 3)Active synchronous malignant neoplasm. 4)Uncontrolled pleural effusion, ascites, or pericardial effusion. 5)Active infection requiring systemic administration of antiviral agents, antifungal agents, or antibiotics. 6)Severe complications. 7)Interstitial pneumonia or pulmonary fibrosis detectable on Xray. 8)History of severe drug allergy 9)Patients unable to be treated with oral medication. 10)Pregnancy or lactating patients. 11)Uncontrolled psychotic disease. 12)Patients who were judged inappropriate to entry this study by physician.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR - Study of targeted Erlotinib treatment for Non-small cell lung cancerStage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFRMedDRA version: 9.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2007-001264-72-GBOxford Radcliffe Hospitals NHS Trust35
已完成
2 期
A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000006078Yamagata University School of Medicine31
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
招募中
2 期
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27